Micro-Sphere increases capsule filling capacity
The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.
Switzerland-based CDMO Micro-Sphere has announced that its MG2 Tekna capsule filling machine is now online, adding further strength to its offering in encapsulation for inhalation products.
Situated in a dedicated cleanroom at Micro-Sphere’s recently expanded facility near Lugano in Ticino, the MG2 Tekna is in an area of controlled relative humidity of 20% (rH 20% +/- 5%), has a production capability of 110,000 cps/hour and increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.
Alongside the MG2 Tekna machine the company has also invested in a MultiNETT, a net weight control system that monitors and reports the net weight of each dosed capsule. The MultiNETT system employs capacitive tomography to guarantee accuracy and precision and rejects all capsules it deems out of specification.
Michael Grassberger has recently been promoted to managing director at Micro-Sphere and is spearheading the company’s plans to increase its client portfolio with its greater capacity and improved services.
He said: “Micro-Sphere has always strived to offer the best possible service to our customers. This investment is the result of increasing client demand for encapsulation services and our drive to offer customers real commercial benefits.
“This new machinery will offer high-quality products, reduced production times, detailed batch reporting and, ultimately, cost savings.
“Added to our existing Harro Höfliger drum dosing equipment the new MG2 Tekna dosator system means we are the only CDMO in the world to offer these two important commercial size filling techniques under one roof.”
This latest announcement is the final step in Micro-Sphere’s 21 million CHF (€19 million) investment plan to expand its GMP manufacturing capabilities and comes as the company celebrates its 20th year in business.
Michael added: “In all of its 20 years our company has been committed to strengthening our niche capabilities in spray drying and inhalables. The expansion has seen a significant investment of time and resource and now enables us to move forward with our planned growth and hopefully garner success for at least another 20 years.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance